Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Total Liabilities (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Total Liabilities data on record, last reported at $1.3 billion in Q3 2025.

  • For Q3 2025, Total Liabilities fell 4.88% year-over-year to $1.3 billion; the TTM value through Sep 2025 reached $1.3 billion, down 4.88%, while the annual FY2024 figure was $1.4 billion, 51.36% up from the prior year.
  • Total Liabilities reached $1.3 billion in Q3 2025 per COLL's latest filing, down from $1.4 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $1.4 billion in Q4 2024 and bottomed at $460.7 million in Q2 2021.
  • Average Total Liabilities over 5 years is $981.4 million, with a median of $1.0 billion recorded in 2022.
  • Peak YoY movement for Total Liabilities: skyrocketed 127.49% in 2022, then dropped 17.4% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $489.1 million in 2021, then soared by 100.2% to $979.3 million in 2022, then decreased by 3.21% to $947.9 million in 2023, then soared by 51.36% to $1.4 billion in 2024, then fell by 7.13% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $1.3 billion in Q3 2025, $1.4 billion in Q2 2025, and $1.4 billion in Q1 2025.